Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Tsuchiya, Kiyoto ^a   Ode, Hirotaka ^b,c   Hayashida, Tsunefusa ^a,d   Kakizawa, Junko ^a   Sato, Hironori ^b   Oka, Shinichi ^a,d   Gatanaga, Hiroyuki ^a,d  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN BINDING;

GENE EXPRESSION REGULATION; GENETICS; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; VARIABLE NUMBER OF TANDEM REPEAT; VIRAL TROPISM; ARTICLE; PROTEIN BINDING;

ARGININE; BASE SEQUENCE; GLYCOSYLATION; HIV ENVELOPE PROTEIN GP120; HIV-1; MINISATELLITE REPEATS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; PROTEIN BINDING; RECEPTORS, CXCR4; VIRAL TROPISM;

EID: 84882417200     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02389     Document Type: Article

References (47)

1. Parra, J. et al. Clinical utility of maraviroc. Clin. Drug Invest. 31, 527-542 (2011).
2. Alkhatib, G. et al. CC CKR5: a RNATES, MIP-1a, MIP-1b receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-1958 (1996).
3. Dragic, T. et al. HIV-1 entry into CD41 cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667-673 (1996).
4. van't Wout, A. B. et al. Macrophage-tropic variant initiate human immunodeficiency virus type 1 infection after sexual, parenteral and vertical transmission. J. Clin. Invest. 94, 2060-2067 (1994).
5. Zhu, T. et al.Genotypic and phenotypic characterization ofHIV-1 in patients with primary infection. Science 261, 1179-1181 (1993).
6. Björndal, A. et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71, 7478-7487 (1997).
7. Scarlatti, G. et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine mediated suppression. Nat. Med. 3, 1259-1265 (1997).
8. Blaak, H. et al. In vivo HIV-1 infection of CD45RA1CD41T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD41T cell decline. Proc. Natl. Acad. Sci. U. S. A. 97, 1269-1274 (2000).
9. Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S. & Landau, N. R. Change in copeceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185, 621-628 (1997).
10. Koot, M. et al. Prognostic value of human immunodeficiency virus type 1 biological phenotype for rate of CD41 cell depletion and progression to AIDS. Ann. Intern. Med. 118, 681-688 (1993).
11. The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. U.S. Department of Health and Human Services (2011).
12. Poveda, E. et al. Genotype determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev. 12, 135-148 (2010).
13. Kawashima, Y. et al. Long-term control of HIV-1 in hemophiliacs carrying slowprogressing allele HLA-B*5101. J. Virol. 84, 7151-7160 (2010).
14. Delobel, P. et al. Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J. Clin. Mcirob. 45, 1572-1580 (2007).
15. Vandekerckhove, L. P. et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect. Dis. 11, 394-407 (2011).
16. Huang, C. C. et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317, 1930-1934 (2007).
17. Yokoyama, M., Naganawa, S., Yoshimura, K.,Matsushita, S. & Sato, H. Structural dynamics of HIV-1 envelope gp120 outer domain with V3 loop. PLoS One 7, e37530 (2012).
18. Naganawa, S. et al. Net positive charge of HIV-1 CRF01-AE V3 sequence regulates viral sensitivity to humoral immunity. PLoS One 3, e3206 (2008).
19. Huang, C. C. et al. Structure of a V3-containing HIV-1 gp120 core. Science 310, 1025-1028 (2005).
20. Clevestig, P., Pramanik, L., Leitner, T. & Ehrnst, A. CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop Nlinked glycosylation site. J. Gen. Virol. 87, 607-612 (2006).
21. Van Baelen, K. et al. HIV-1 coreceptor usage determination in clinical isolates using cloncal and population-based genotypic and phenotypic assays. J. Virol. Methods 146, 61-73 (2007).
22. Schnur, E. et al. The conformation and orientation of a 27-residue CCR5 peptide in a ternary complex with HIV-1 gp120 and a CD4-mimic peptide. J. Mol. Biol. 410, 778-797 (2011).
23. Pejchal, R. et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097-1103 (2011).
24. Kuwata, T. et al. Conformational epitope consisting of the V3 and V4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses. J. Virol. 87, 5424-5436 (2013).
25. Cecilia, D. et al. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J. Virol. 72, 6988-6996 (1998).
26. Brown, B. K. et al. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01-AE, and CRF02-AG, for the development and assessment of candidate vaccines. J. Virol. 79, 6089-6101 (2005).
27. Whitcomb, J. M. et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51, 566-575 (2007).
28. Jensen, M. A. & van't Wout, A. B. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev. 5, 104-112 (2003).
29. Sing, T. et al. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir. Ther. 12, 1097-1106 (2007).
30. Jensen, M. A. et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol. 77, 13376-13388 (2003).
31. Low, A. J. et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 21, F17-24 (2007).
32. Poveda, E. et al. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J. Antimicrob. Chemother. 63, 1006-1010 (2009).
33. Arroyo, M. A. et al.Virologic risk factors for vertical transmission of HIV type 1 in Puerto Rico. AIDS Res. Hum. Retroviruses 18, 447-460 (2002).
34. Mörner, A. et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73, 2343-2349 (1999).
35. Maeda, K. et al. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition. J. Mol. Biol. 381, 956-974 (2008).
36. Maeda, Y., Foda, M.,Matsushita, S. & Harada, S. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J. Virol. 74, 1787-1793 (2000).
37. Koyanagi, Y. et al. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236, 819-822 (1987).
38. Martí-Renom, M. A. et al. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 29, 291-325 (2000).
39. Baker, D. & Sali, A. Protein structure prediction and structural genomics. Science 294, 93-96 (2001).
40. Kollman, P. A. et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 33, 889-897 (2000).
41. Pearlman, D. A. et al. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comp. Phys. Commun. 91, 1-41 (1995).
42. Hsieh, M. J. & Luo, R. Balancing Simulation Accuracy and Efficiency with the Amber United Atom Force Field. J. Phys. Chem. B 114, 2886-2893 (2010).
43. Hawkins, G. D., Cramer, C. J. & Truhlar, D. G. Parametrized models of aqueous free energies of solvation based on pairwise descreening of solute atomic charges from a dielectric medium. J. Phys. Chem. 100, 19824-19839 (1996).
44. Hawkins, G. D., Cramer, C. J. & Truhlar, D. G. Pairwise solute descreening of solute charges from a dielectric medium. Chem. Phys. Lett. 246, 122-129 (1995).
45. Shao, J., Tanner, S. W., Thompson, N. & Cheatham, T. E. 3rd. Clustering molecular dynamics trajectories: 1. Characterizing the performance of different clustering algorithms. J. Chem. Theory Comput. 3, 2312-2334 (2007).
46. Westervelt, P., Gendelman, H. E. & Ratner, L. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc. Natl. Acad. Sci. U. S. A. 88, 3097-3101 (1991).
47. Jekle, A. et al. Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. J. Virol. 76, 6966-6973 (2002).